Eikance 0.01% is the first pharmacotherapy registered on the Australian Register of Therapeutic Goods to slow the progression of myopia in children aged four to 14 years, and may be initiated in children when myopia progresses ≥-1.0 D per year.1#
Eikance 0.01% single-use ampoules are sealed in foil pouches and available in packs of 30 x 0.3 mL ampoules. The ophthalmic solution is sterile and preservative-free. Eikance 0.01% is a private, prescription only medicine available at community pharmacies across Australia.
Contact: Aspen Account Manager
References
- Eikance Approved Product Information.
# Australian Register of Therapeutic Goods [accessed 15 August 2023]. Prepared: August 2023. AU-ATR-082023-06771.
